AstraZeneca's lung cancer trial success hailed by broker

AstraZeneca secured FDA accelerated approval for Datroway, an antibody-drug conjugate (ADC) developed with Daiichi Sankyo, for advanced non-small cell lung cancer patients who have undergone prior treatment. This precision therapy is considered a significant advancement, central to AZ's ambitious oncology strategy, with analysts projecting peak sales potential of $4-8 billion. Shore Capital maintains a positive long-term growth outlook for AstraZeneca, citing a fair valuation of 15,000p (18x 2026E earnings), as the company awaits key Phase III AVANZAR trial results later this year for Datroway's first-line lung cancer potential.

Analysis

AstraZeneca has secured accelerated FDA approval for Datroway, an antibody-drug conjugate (ADC) developed with Daiichi Sankyo, for treating advanced non-small cell lung cancer patients who have received prior therapies. This approval marks a strategic advancement in the company's oncology franchise, reinforcing its ambition to make over half of lung cancer patients eligible for its medicines by 2030. According to Shore Capital, the drug holds significant commercial potential, with peak sales estimates ranging from a risk-adjusted US$4 billion to a non-risk-adjusted US$8 billion. A critical upcoming catalyst is the result from the Phase III AVANZAR trial, expected later this year, which will evaluate Datroway's efficacy as a first-line treatment and is pivotal for realizing its full market potential. From a valuation perspective, AstraZeneca's shares trade at approximately 13.6 times projected 2026 earnings, a slight premium to its peer group but below its historical norms, while ShoreCap maintains a fair value estimate of 15,000p, implying an 18x earnings multiple. While the outlook is positive, investors should note that sector-wide volatility linked to US political uncertainties is a stated risk.

Key Decisions for Investors

• Investors should closely monitor the upcoming Phase III AVANZAR trial results later this year, as a positive outcome for first-line lung cancer treatment is the primary catalyst for unlocking Datroway's full commercial potential and justifying a higher valuation.
• While the current valuation at 13.6x 2026E earnings is above peers, it may be warranted given the pipeline progress; however, significant stock appreciation towards the 15,000p analyst target is likely contingent on continued clinical success, particularly in first-line settings.
• It is important to recognize that the current approval is for a limited, later-line patient population and to factor in potential short-term volatility stemming from US political uncertainties that could impact the broader pharmaceutical sector.